In the work by Kreig, C, et al., higher frequencies of CD14+ CD16- HLA-DR+ CD64+ monocytes were shown to be a positive indicator for anti-tumor responses in anti-PD-1 therapy measured by progression-free survival and overall survival in responders compared to non-responders in stage IV melanoma (53). This evidence concerns the gene FCGR3A and neoplasm.